global
Variables
Utilities
CUSTOM STYLES

First Immunotherapy Treatment Approved for Stage III

February 16, 2018

Friday, February 16, 2018. Today the Food and Drug Administration (FDA) approved Imfinzi (durvalumab), the first immunotherapy drug for stage III non-small cell lung cancer. This approval is what is called "maintenance" therapy, which is when you take a drug to help prevent cancer from growing or coming back following earlier treatment protocols. Learn more now.

This is some text inside of a div block.

Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.